Industry
What’s the deal with Alzheimer’s disease and amyloid?
This Ars Technica article examines the complex relationship between amyloid plaques and Alzheimer's disease, including the long-debated 'amyloid cascade hypothesis' and its role in driving disease res
This Ars Technica article examines the complex relationship between amyloid plaques and Alzheimer's disease, including the long-debated "amyloid cascade hypothesis" and its role in driving disease research and treatment. It likely covers the recent milestone of FDA-approved anti-amyloid therapies — lecanemab (Leqembi) and donanemab (Kisunla), two treatments designed to clear toxic amyloid-beta from the brain — while also addressing ongoing scientific questions about how central amyloid truly is to the disease. Given the explainer-style title, the piece likely contextualizes why amyloid has been both celebrated and controversial, noting that researchers are studying next-generation amyloid-clearing therapies while also exploring other avenues to slow disease progression , reflecting a broader scientific debate about whether amyloid is a cause, a symptom, or just one piece of a much larger puzzle.
Related
Source: Ars Technica | 2026-04-15